Sanofi's Combo Vaccines Gain FDA Fast Track Designation
Antisense & RNAi Therapeutics Market Report 2024, Featuring Profiles of Alnylam Pharmaceuticals, Arbutus Biopharma, Benitec Biopharma, GSK, Ionis Pharmaceuticals, Sanofi, Sarepta Therapeutics & More - ResearchAndMarkets.com
Express News | Sanofi's Dual Influenza-COVID-19 Vaccines Receive FDA Fast Track Designation For Individuals 50 Years Of Age And Older
Press Release: Two Combination Vaccine Candidates for Prevention of Influenza and COVID-19 Granted Fast Track Designation in the US
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF) and NovoCure (NVCR)
AQEMIA Hits $100 Million Funding Milestone, Paving Way to Clinical Trials and Global Expansion Starting With London, UK
